Schedule An Appointment
(631) 675-5075
Career Openings
Español
中國傳統的
简体中文
Locations
Care Team
Locations
Care Team
All Doctors
Medical Oncologists
Radiation Oncologists
Breast Surgeons
Surgical Oncologist
Support/Palliative
Behavioral Health
Registered Dietitian Nutritionists
Our APPs
Patients
Accepted Insurance
Appointments
Blood Disorders
Cancers
Carespace Portal
Fill my Prescription
Make A Payment
Mammography
Medical Marijuana
Patient Advocacy
Physical Therapy
Radiology
Professionals
Patient Referral
Clinical Trials
Our Research Center
Our Research Team
Career Opportunities
News & Events
NCCN Guidelines
Oncology Medical Home (OMH)
Research
About Research
Common Questions
Study Participation
Our Research Center
Our Research Team
Clinical Trials
About
About Us
News & Updates
Our Leadership
Our Difference
Our Friends
Our Services
Medical Oncology
Radiation Oncology
Hematology
Fill My Prescription
Physical Therapy
Health & Wellness
Laboratory Testing
Personalized Medicine
Diagnostic Imaging
Other Services
Career Opportunities
Opportunities
Request for Educational Opportunities
Newsletters
Our Current Trials
Condition
Trial Name
Sponsor
Solid Tumors
1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors
Mirati Therapeutics, Inc.
Rectal Cancer
19-288: Neoadjuvant TSR-042 (dostarlimab) for Patients with Rectal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Chronic Myelogenous Leukemia
ASC2ESCALATE: Asciminib Monotherapy as First or Second Line Treatment
Novartis Pharmaceuticals
Breast Cancer
ASCENT-03: Sacituzumab Govitecan as First Line Treatment for Patients With Triple Negative Breast Cancer
Gilead Sciences
Breast Cancer
ASCENT-04: Sacituzumab Govitecan in Combination With Pembrolizumab as First Line Treatment for Patients With PD-L1 Expressing Triple Negative Breast Cancer
Gilead Sciences
Breast Cancer
ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer
Gilead Sciences, Inc.
Cachexia in Colorectal or Pancreatic Cancer
AV-380-22-102: Study of GDF-15 Inhibitor AV-380 for the Treatment of Cachexia in Patients with Metastatic Colorectal or Pancreatic Cancer Receiving First Line Chemotherapy
AVEO Pharmaceuticals, Inc.
Colon Cancer
AZUR-2: Perioperative Dostarlimab in Patients with dMMR/MSI-H Resectable Colon Cancer
GlaxoSmithKline
Solid Tumors
BI 1403-0001: MDM2 inhibitor BI 907828 in MDM2 Amplified Advanced Solid Tumors
Boehringer Ingelheim
HER2 Expressing Solid Tumors
BL-M07D1-ST-101: Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune Inc.
Breast Cancer
BRIA-ABC: Bria-IMT plus Immunotherapy for Patients with Pre-Treated Metastatic Breast Cancer
BriaCell Therapeutics Corporation
Solid Tumor or Lymphoma
CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
CStone Pharmaceuticals
Non-Small Cell Lung Cancer
EIK1001-005: EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer
Eikon Therapeutics
Breast Cancer
ELEVATE: Elacestrant Combinations for the Treatment of ER+ HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor
Stemline Therapeutics, Inc.
Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2: Epcoritamab in Combination with R-CHOP vs R-CHOP Alone as First Line Treatment
AbbVie
Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
EPCORE: Epcoritamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
AbbVie Inc.
Central Nervous System Cancer
F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy
Fore Biotherapeutics
Solid Tumors
F8394-201a: BRAF Inhibitor FORE8394 for the Treatment of BRAF Fusion Positive Advanced Solid Tumors
Fore Biotherapeutics
Breast Cancer
First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer
Regor Pharmaceuticals Inc.
Gastric or Gastroesophageal Junction Cancer
GEMINI-C: First Line Treatment for Patients with an Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Colorectal Cancer
INTRINSIC: A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer
Hoffmann-La Roche
Non-Small Cell Lung Cancer
KRYSTAL-17: Adagrasib Combinations in Patients with KRAS G12C Mutation
Mirati Therapeutics, Inc.
Colon or Rectal Cancer
LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash
Lutris Pharma Ltd.
Non-Hodgkin Lymphoma
MorningSun: Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
Genentech, Inc.
Hyperkalemia/Chronic Kidney Disease
NYH-01: Hyperkalemia/Chronic Kidney Disease
Relypsa
Breast Cancer
OPERA-01: OP-1250 (palazestrant) in ER-Positive and HER2-Negative Metastatic Breast Cancer Previously Treated with a CDK4/6 Inhibitor
Olema Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals
ITP, wAIHA, CAD
RUBY-4: Povetacicept (ALPN-303) for Patients with Autoimmune Cytopenias
Alpine Immune Sciences, Inc.
Breast Cancer
SERENA-6: AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression
AstraZeneca
Solid Tumors
STELLAR-009: Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab
Exelixis
Head and Neck Squamous Cell Carcinoma
STELLAR-305: Zanzalintinib in Combination with Pembrolizumab as First Line Therapy for Recurrent or Metastatic Disease
Exelixis
Non-Small Cell Lung Cancer
TROPION-Lung07: Datopotamab Deruxtecan Combinations vs Standard Chemo/Immunotherapy for the First Line Treatment of Non-Squamous Non-Small Cell Lung Cancer
Daiichi Sankyo, Inc.
Cancer Diagnosis
[Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients
Memorial Sloan Kettering Cancer Center
Various Indications
[Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx)
Precision for Medicine
Solid Tumors
[Sample Collection] Collection and Distribution of Biofluids for Research Purposes
Bluestar Genomics
Solid Tumors
[Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2)
Exact Sciences Thrive LLC
Various Indications
[Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022)
MT Group
Various Indications
[Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035)
SERATRIALS, LLC.
Solid Tumors
[Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
Freenome Holdings Inc.
Call Us
(631) 675-5075
Contact us today to request an appointment.
Virtual & Telemedicine available.
Request Appointment